A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma

Abstract excerpt

The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA gene mutations in cancer
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy